Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling.

Daniel PM, Filiz G, Mantamadiotis T.

Cell Death Dis. 2016 Dec 1;7(12):e2494. doi: 10.1038/cddis.2016.393.

2.

Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk.

Rubin JB.

Mol Cell Oncol. 2015 Aug 3;3(3):e1069917. doi: 10.1080/23723556.2015.1069917.

3.

The role of microglia and macrophages in glioma maintenance and progression.

Hambardzumyan D, Gutmann DH, Kettenmann H.

Nat Neurosci. 2016 Jan;19(1):20-7. doi: 10.1038/nn.4185. Review.

4.

Targeting brain tumor cAMP: the case for sex-specific therapeutics.

Warrington NM, Sun T, Rubin JB.

Front Pharmacol. 2015 Jul 28;6:153. doi: 10.3389/fphar.2015.00153.

5.

In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells.

Allouche J, Bellon N, Saidani M, Stanchina-Chatrousse L, Masson Y, Patwardhan A, Gilles-Marsens F, Delevoye C, Domingues S, Nissan X, Martinat C, Lemaitre G, Peschanski M, Baldeschi C.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):9034-9. doi: 10.1073/pnas.1501032112.

6.

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, Goumnerova LC, Ligon AH, Stiles C, Segal R, Golub T, Grill J, Ligon KL, Chan JA, Kieran MW, Beroukhim R.

Neuro Oncol. 2015 Nov;17(11):1486-96. doi: 10.1093/neuonc/nov045.

7.

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, Fisher MJ, Tabori U, Allen JC, Schiffman JD, Gutmann DH, Rubin JB.

Cancer Res. 2015 Jan 1;75(1):16-21. doi: 10.1158/0008-5472.CAN-14-1891.

8.

PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.

Brooks MD, Jackson E, Warrington NM, Luo J, Forys JT, Taylor S, Mao DD, Leonard JR, Kim AH, Piwnica-Worms D, Mitra RD, Rubin JB.

PLoS One. 2014 Sep 9;9(9):e107397. doi: 10.1371/journal.pone.0107397.

9.

Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males.

Sun T, Warrington NM, Luo J, Brooks MD, Dahiya S, Snyder SC, Sengupta R, Rubin JB.

J Clin Invest. 2014 Sep;124(9):4123-33. doi: 10.1172/JCI71048.

10.

Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.

Anastasaki C, Gutmann DH.

Hum Mol Genet. 2014 Dec 20;23(25):6712-21. doi: 10.1093/hmg/ddu389.

11.

Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Gutmann DH.

Neurology. 2014 Jul 29;83(5):463-71. doi: 10.1212/WNL.0000000000000652. Review.

12.

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, Cho W, Lim K, Xu J, Lazar AJ, Creighton CJ, Bolshakov S, McKay RM, Lev D, Le LQ, Parada LF.

Cell. 2013 Feb 28;152(5):1077-90. doi: 10.1016/j.cell.2013.01.053.

13.

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma.

Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L, Mardis ER.

Genome Res. 2013 Mar;23(3):431-9. doi: 10.1101/gr.142604.112.

14.

Pathological and molecular advances in pediatric low-grade astrocytoma.

Rodriguez FJ, Lim KS, Bowers D, Eberhart CG.

Annu Rev Pathol. 2013 Jan 24;8:361-79. doi: 10.1146/annurev-pathol-020712-164009. Review.

15.

Neurofibromatosis type 1: modeling CNS dysfunction.

Gutmann DH, Parada LF, Silva AJ, Ratner N.

J Neurosci. 2012 Oct 10;32(41):14087-93. doi: 10.1523/JNEUROSCI.3242-12.2012. Review.

16.

BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.

Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, Rushing EJ, Ligon KL, Vena N, Garcia DI, Cameron JD, Eberhart CG.

J Neuropathol Exp Neurol. 2012 Sep;71(9):789-94. doi: 10.1097/NEN.0b013e3182656ef8.

17.

Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma.

Phillips JJ, Huillard E, Robinson AE, Ward A, Lum DH, Polley MY, Rosen SD, Rowitch DH, Werb Z.

J Clin Invest. 2012 Mar;122(3):911-22. doi: 10.1172/JCI58215.

18.

MAPK pathway activation in pilocytic astrocytoma.

Jones DT, Gronych J, Lichter P, Witt O, Pfister SM.

Cell Mol Life Sci. 2012 Jun;69(11):1799-811. doi: 10.1007/s00018-011-0898-9. Review.

19.

Along-tract statistics allow for enhanced tractography analysis.

Colby JB, Soderberg L, Lebel C, Dinov ID, Thompson PM, Sowell ER.

Neuroimage. 2012 Feb 15;59(4):3227-42. doi: 10.1016/j.neuroimage.2011.11.004.

20.

Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth.

Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB.

Mol Cancer Res. 2012 Jan;10(1):156-66. doi: 10.1158/1541-7786.MCR-11-0411.

Supplemental Content

Support Center